SRH Advisors’s CRISPR Therapeutics CRSP Stock Holding History

SRH Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15	Closed	-$787	–	285
2025 Q4	$787	Hold	15	–	–	﹤0.01%	286
2025 Q3	$972	Buy	+15	New	+$861	﹤0.01%	268

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SRH Advisors's CRSP Position: Q1 2026 in Review

SRH Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 15 shares — an estimated $787 sold.

SRH Advisors first reported a position in CRSP in Q3 2025 and held it in 2 quarters. The position peaked at $972 in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

SRH Advisors reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
SRH Advisors sold 15 CRISPR Therapeutics shares in Q1 2026, an estimated $787.
SRH Advisors first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 2 quarters.
SRH Advisors's CRISPR Therapeutics position peaked at $972 in Q3 2025.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on SRH Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.